EN DE
Data-driven stock valuation

Caris Life Sciences, Inc. Common Stock (CAI) fair value: what the stock is really worth

We calculate from audited financials what Caris Life Sciences, Inc. Common Stock is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $5.2B · ISIN US1421521071

At a glance

CL Caris Life Sciences, Inc. Common Stock logo Caris Life Sciences, Inc. Common Stock CAI · US
Price$24.82
Fair Value$3.56
Upside−85.7% ⚠
Quality47/100

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Below-average quality, and trading another 597% above our fair value of $3.56.

As of Sep 5, 2026, the fair value of Caris Life Sciences, Inc. Common Stock is $3.56 per share against a price of $24.82, so the fair value sits 86% below the price. A model estimate from reported figures, not an analyst target.

!Mixed Growth (revenue 5y +22.5 %/yr)
!Thin margins · 3.8% net margin
✓Moderate debt · generates free cash flow
✓Ranks above peers (6/9)
!Moderate moat 49/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 7 out of 100
Evidence: Low Range $2.99 to $4.14

Fair value as of: Sep 5, 2026

From 15 valuation models · updated 4 days ago

Share price +9.1% over the past month.

Watch Caris Life Sciences, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($4.14). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (15 months)

$39.30 $14.55 Fair Value $3.56 Jun 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.

How to read this chart

15‑month range $14.55 – $39.30 · fair‑value band $2.99 – $4.14 · the $24.82 price screens above the $3.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Caris Life Sciences, Inc. Common Stock (CAI) currently trades at $24.82, while our model-based Fair Value estimate is $3.56, implying the stock looks roughly 596.9% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $6.51 per share, and 0 of the 15 models we run sit above the $24.82 price. Bear case: the Dividend Discount group reads lowest at $0.9500, and 15 of the 15 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Caris Life Sciences, Inc. Common Stock generated revenue of $907M at a net margin of 3.8%. Revenue grew 78.8% year over year. It earns a return on equity of 28.4%. The balance sheet holds a net cash position of $419M. Fundamentals as of Sep 5, 2026

Scenario range: $2.99 (bear) to $4.14 (bull), the price of $24.82 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 42% below its 52-week high and 75% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −86%, CAI screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely ($0.9500 to $7.84). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF $4.98 $7.28 $13.61 77
Growth DCF $4.82 $7.84 $13.36 76
5Y EBITDA Exit $4.24 $6.51 $10.51 74
All 15 models by family
DCF Models
FCF DCF $4.98 $7.28 $13.61 77
5Y Revenue Exit $3.58 $5.07 $7.85 72
5Y EBITDA Exit $4.24 $6.51 $10.51 74
10Y Revenue Exit $3.94 $5.89 $8.15 67
10Y EBITDA Exit $4.45 $7.10 $11.77 67
Earnings-Based
EPV $2.21 $2.32 $2.42 74
Dividend Discount
Gordon GGM $0.5500 $1.10 $1.66 67
DDM Multi-Stage $0.5500 $0.9500 $1.16 67
Multiples
EV/EBIT $3.52 $4.20 $4.87 66
EV/EBITDA $4.00 $4.84 $5.68 67
EV/Revenue $2.94 $3.56 $4.18 54
Asset-Based
NCAV (Graham) $1.02 $1.37 $2.04 54
Growth DCF
Growth DCF $4.82 $7.84 $13.36 76
Rev-Margin DCF $3.58 $5.27 $7.77 72
Economic Profit
ROIC Compounder $2.33 $2.72 $3.00 72

Widest divergence: DCF Models ($6.51) versus Dividend Discount ($0.9500). Highest evidence: FCF DCF (77).

Notify me when CAI reaches fair value

Put CAI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 5.75 TTM
EPS (TTM) $−2.76
Dividend yield 0.3%
Net margin −66.2% FY2025
Return on equity 28.4% TTM
Return on assets (EBIT) −37.4% avg 5y
More key figures
Profitability
Operating margin 2.4% TTM
Growth
Revenue (TTM) $907M TTM
Revenue growth (YoY) +78.8% 3y avg +46.5%
Balance sheet & cash flow
Free cash flow $66.9M FY2025
Net cash $419M FY2025

Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 47/100

Of which business quality 48 · Market factors (momentum, volatility) 31

Profitability 27
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 54
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 60
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 20
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.

Full company description

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2025 · reported fiscal years

Caris Life Sciences, Inc. Common Stock reported revenue of $812M in FY2025 versus $294M in FY2020, a compound +22.5%/yr. Reported net income was −$538M in FY2025.

Growth Quality 78/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$812M
Latest YoY
+97.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+46.5%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+22.5%
Avg. revenue growth/yr (22Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+13.7%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
31.3% (2019) → −62.4% (2024)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue +22.5%/yr
FY20 $294M
FY22 $258M
FY23 $306M
FY24 $412M
FY25 $812M
Net income
FY20 $27.7M
FY22 −$321M
FY23 −$341M
FY24 −$282M
FY25 −$538M

CAI screens 597% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Caris Life Sciences, Inc. Common Stock · Fair Value
$3.56 −597%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Caris Life Sciences, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/CAI

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Biotechnology · 632 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 47 · Above median
Fair Value upside −86% · Bottom 25%
Profitability
Return on equity (TTM) 28% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 4% · Above median
Operating margin (TTM) 2% · Above median
Growth and dividend
Revenue growth 79% · Top 25%
Dividend yield (TTM) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.66× · Highest 25%

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 9.04× · Priciest 25%
P/S (TTM) 5.76× · Pricier than median
P/FCF 78.0× · Priciest 25%
EV/EBITDA 37.2× · Priciest 25%

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Caris Life Sciences, Inc. Common Stock deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years+57.7 % per year
Achieved revenue growth, 5 years+22.5 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price0.16 %
Discount rate (WACC) in the models9.7 %

The price demands an acceleration versus past growth: a high bar the company still has to clear. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 0
PAST100 · sector 0
HEALTH67 · sector 98
DIVIDEND7 · sector 25

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,518,000 KRW 1,055,793 KRW −30%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE 22UA €80.60 €52.92 −34%
Incyte Corporation INCY $123.22 $115.79 −6%

Compare Caris Life Sciences, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Caris Life Sciences, Inc. Common Stock (CAI) overvalued or undervalued?
As of Sep 5, 2026, our model estimates a fair value of $3.56 versus a price of $24.82, about −86% upside (overvalued).
What is the fair value of CAI?
Our model-based fair value for Caris Life Sciences, Inc. Common Stock is $3.56 (as of Sep 5, 2026), built from audited fundamentals. The current price: $24.82.
What is the quality score of CAI?
Caris Life Sciences, Inc. Common Stock has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caris Life Sciences, Inc. Common Stock (CAI)?
Our model-based price target is the fair value of $3.56 (as of Sep 5, 2026) from 15 valuation models. Cautious scenario $2.99, optimistic scenario $4.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Caris Life Sciences, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $3.56, about −86% upside versus a price of $24.82 (overvalued). Cautious scenario $2.99, optimistic scenario $4.14. The calculation is refreshed regularly with new filings.
What is the revenue of Caris Life Sciences, Inc. Common Stock (CAI)?
Caris Life Sciences, Inc. Common Stock reported trailing-twelve-month revenue of about $907M (latest available figure, as of Sep 5, 2026).
What is the net profit margin of CAI?
The net profit margin of Caris Life Sciences, Inc. Common Stock is about 3.8%, meaning it keeps roughly 3.8% of revenue as net income. Based on the latest reported figures.
Does Caris Life Sciences, Inc. Common Stock pay a dividend?
Caris Life Sciences, Inc. Common Stock currently shows a dividend yield of about 0.34% relative to its recent price (as of Sep 5, 2026).
What growth is priced into Caris Life Sciences, Inc. Common Stock (CAI)?
For today's price to be fair in a discounted-cash-flow model, Caris Life Sciences, Inc. Common Stock would have to grow free cash flow by +57.7 % per year for ten years (discount rate 9.7 %, then 2 % perpetual growth). Over the last 5 years revenue grew +22.5 % per year. As of Sep 5, 2026.
What discount rate (WACC) does the fair value of CAI use?
Our models discount Caris Life Sciences, Inc. Common Stock at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is the intrinsic value of Caris Life Sciences, Inc. Common Stock (CAI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caris Life Sciences, Inc. Common Stock it is $3.56 per share (as of Sep 5, 2026), against a price of $24.82. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Caris Life Sciences, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 5, 2026, CAI trades above its calculated fair value: price $24.82, fair value $3.56, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAI?
No. The price is what the market pays today ($24.82); the fair value is what the company's own numbers justify ($3.56). For Caris Life Sciences, Inc. Common Stock the two are $21.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Caris Life Sciences, Inc. Common Stock worth?
The market values Caris Life Sciences, Inc. Common Stock at about $5.2B (market capitalisation, as of Sep 5, 2026). Per share that is $24.82; our models calculate a fair value of $3.56 per share.
What do the bullish and bearish scenarios say about CAI?
Our models span a range for Caris Life Sciences, Inc. Common Stock: cautious scenario $2.99, base $3.56, optimistic $4.14 per share (as of Sep 5, 2026, price $24.82). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Caris Life Sciences, Inc. Common Stock (CAI)?
Balance-sheet figures for Caris Life Sciences, Inc. Common Stock (as of Sep 5, 2026): return on equity 28.4%, debt of 0.66 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is CAI from its 52-week high?
Caris Life Sciences, Inc. Common Stock trades at $24.82, about 42% below its 52-week high of $42.50 and 75% above the low of $14.19 (as of Sep 5, 2026). Distance from the high says nothing about value: that is what the fair value of $3.56 is for.
Which stocks are comparable to Caris Life Sciences, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caris Life Sciences, Inc. Common Stock stock attractive at the current price?
The data as of Sep 5, 2026: price $24.82, calculated fair value $3.56 (−86%), Quality Score 47/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAI calculated?
We run Caris Life Sciences, Inc. Common Stock through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.56, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed

Watch Caris Life Sciences, Inc. Common Stock in the live analysis

One click puts Caris Life Sciences, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.